Teijin Pharma Limited announced the European launch of TMX-67
(febuxostat), a novel drug discovered by for the treatment
of hyperuricemia in patients with gout.
Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
About ADENURIC(r)
Product name: ADENURIC(r)
Generic name: febuxostat
Pharmaceutical Forms and Strength: film-coated tablets, 80mg and 120mg
Therapeutic Indications: Treatment of chronic hyperuricemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis)
Dosage and Administration: 80 mg once daily without regard to food. If serum uric acid is >6 mg/dl after 2-4 weeks, 120mg once daily may be considered
Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
Gout, a chronic disease marked by gouty arthritis associated with severe
pain, is mainly treated with medication that inhibits xanthine oxidase,
an enzyme directly related to the production of uric acid. The current
leading medication, allopurinol, was developed nearly 40 years ago, so a
new drug that provides more options for the treatment of gout and
hyperuricemia has long been sought.
TMX-67, developed by Teijin Pharma after intensive research, is an oral,
once-daily, highly potent, non-purine selective inhibitor of xanthine
oxidase.
TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.
TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment.
About ADENURIC(r)
Product name: ADENURIC(r)
Generic name: febuxostat
Pharmaceutical Forms and Strength: film-coated tablets, 80mg and 120mg
Therapeutic Indications: Treatment of chronic hyperuricemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis)
Dosage and Administration: 80 mg once daily without regard to food. If serum uric acid is >6 mg/dl after 2-4 weeks, 120mg once daily may be considered
No comments:
Post a Comment